0
0.5
1
1.5
2+
Mortality
61%
Improvement
Relative Risk
ICU admission
56%
Progression
59%
Sotrovimab for COVID-19 Ong et al. EARLY TREATMENT
Is early treatment with sotrovimab beneficial for COVID-19?
Retrospective 94 patients in Singapore
Lower progression with sotrovimab (p=0.047)
c19early.org
Ong et al., Antibiotics, March 2022
Favors sotrovimab
Favors control